Business
Idorsia reports strong Q1 2026 performance with 74% QUVIVIQ sales growth year-on-year
Ad hoc announcement pursuant to Art. 53 LR Preparation is underway to publish the strong pediatric daridorexant data and engage with regulatory authorities on next stepsCo-promotion of QUVIVIQ is being expanded across additional European markets to further accelerate growthPartnering discussions for TRYVIO™/JERAYGO™ are ongoing with several parties Allschwil, Switzerland – April 28, 2026Idorsia Ltd (SIX: IDIA), a commercial-stage biopharmaceutical company with a portfolio of first- or best-in-cl
About this update from Idorsia Ltd.
[{"type":"image","alt":"Idorsia Pharmaceuticals Ltd","displaySize":"","headline":null,"caption":"Idorsia Pharmaceuticals Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":138,"url":"https://media.zenfs.com/en/globenewswire.com/78a4ac48860a5805262d0e653fb52e9a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hFCnMmy9Ihh7UbzaqwJr7A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5Mw--/https://media.zenfs.com/en/globenewswire.com/78a4ac48860a5805262d0e653fb52e9a","width":300,"height":138}},"lazy":false},{"type":"text","content":"Ad hoc announcement pursuant to Art. 53 LR","length":42,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Preparation is underway to publish the strong pediatric daridorexant data and engage with regulatory authorities on next steps","length":126,"tagName":"p"}]},{"val":[{"type":"text","content":"Co-promotion of QUVIVIQ is being expanded across additional European markets to further accelerate growth","length":105,"tagName":"p"}]},{"val":[{"type":"text","content":"Partnering discussions for TRYVIO™/JERAYGO™ are ongoing with several parties","length":76,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":307,"olType":false},{"type":"text","content":"Allschwil, Switzerland – April 28, 2026Idorsia Ltd (SIX: IDIA), a commercial-stage biopharmaceutical company with a portfolio of first- or best-in-class assets, today announced its financial results for the first quarter of 2026.","length":230,"tagName":"p"},{"type":"text","content":"Jean-Paul Clozel, Chairman and interim CEO of Idorsia, commented:“We have made a strong start to 2026. QUVIVIQ sales are tracking in line with our expectations, our pipeline is advancing, and we have delivered excellent results with daridorexant in children. Our focus is now firmly on executing the actions that will accelerate growth and unlock Idorsia’s full value. Building on the solid foundation established by our commercial team, we are working to further change the sales trajectory and accelerate growth, generating the cash flow required to continue advancing our breakthrough portfolio.”","length":600,"tagName":"p"},{"type":"text","content":"QUVIVIQ® (daridorexant)","length":23,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"QUVIVIQ continues to reshape the insomnia treatment landscape, and Idorsia is investing to a...